Investors might want to bet on Health Catalyst (HCAT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors o ...

Core Viewpoint - Plus Therapeutics (PSTV) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling activities [3]. Company Performance Indicators - The upgrade for Plus reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Over the past three months, the Zacks Consensus Estimate for Plus has increased by 78.7%, indicating a significant upward revision in earnings expectations [7]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - Plus's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Core Viewpoint - Sallie Mae (SLM) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors [4][6]. - For Sallie Mae, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to a higher stock price [5][10]. Earnings Estimate Revisions - Sallie Mae is projected to earn $3.12 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.6% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10].

Core Viewpoint - Oric Pharmaceuticals, Inc. (ORIC) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Oric Pharmaceuticals reflects an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, influencing their buying and selling actions, which subsequently affects stock prices [5]. Recent Performance of Oric Pharmaceuticals - For the fiscal year ending December 2025, Oric Pharmaceuticals is expected to earn -$1.75 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 15.7% over the past three months [9]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [8]. - Oric Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Barclays (BCS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ...

Group 1 - Arcosa (ACA) closed at $87.00, with a 2.1% gain over the past four weeks, and a mean price target of $109.2 indicating a 25.5% upside potential [1] - The average price target ranges from a low of $100.00 to a high of $120.00, with a standard deviation of $7.29, suggesting a 14.9% to 37.9% upside [2] - Analysts show strong agreement on ACA's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ACA has increased by 1.1% due to one upward revision in earnings estimates over the last 30 days [12] - ACA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [14]

A downtrend has been apparent in Paycom Software (PAYC) lately with too much selling pressure. The stock has declined 9.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversol ...

Core Viewpoint - Intellicheck Mobilisa, Inc. (IDN) shows potential as a stock pick due to its recent technical performance, surpassing resistance levels and indicating a bullish trend [1]. Technical Analysis - IDN has recently moved above its 20-day simple moving average, which is a positive indicator for short-term traders as it suggests a bullish trend [2]. - The stock has increased by 24.1% over the past four weeks, reinforcing the positive technical outlook [4]. Earnings Estimates - There have been two upward revisions in IDN's earnings estimates for the current fiscal year, with no downward revisions, indicating strong investor confidence [4]. - The consensus earnings estimate has also increased, further supporting the bullish sentiment around IDN [4][5].

Core Insights - Winnebago Industries (WGO) is expected to report quarterly earnings of $0.79 per share, reflecting a decline of 30.1% year-over-year, with revenues forecasted at $775.32 million, a decrease of 1.4% compared to the previous year [1] - The consensus EPS estimate has been revised downward by 31.6% in the last 30 days, indicating a significant reassessment by analysts [2] - Analysts emphasize the importance of earnings projection revisions as they are closely linked to short-term stock price performance [3] Revenue Projections - Analysts estimate 'Net Revenues- Motorhome RV' at $280.31 million, down 6.3% year-over-year [5] - 'Net Revenues- Marine' is projected to reach $97.21 million, an increase of 10.6% from the prior year [5] - 'Net Revenues- Corporate / All Other' is expected to be $14.03 million, reflecting a 9.6% increase year-over-year [5] - 'Net Revenues- Towable RV' is forecasted at $414.40 million, indicating a 7.3% increase from the previous year [6] Unit Deliveries - Total Motorhome RV unit deliveries are expected to be 1,414, down from 1,680 in the same quarter last year [6] - Total Towable RV unit deliveries are projected at 10,355, compared to 9,263 in the same quarter last year [6] - Marine boat unit deliveries are anticipated to reach 1,303, up from 1,127 in the same quarter last year [7] EBITDA Estimates - Adjusted EBITDA for Towable RV is expected to be $41.66 million, slightly down from $41.90 million year-over-year [7] - Adjusted EBITDA for Marine is projected at $10.78 million, up from $8.50 million in the previous year [7] - Adjusted EBITDA for Motorhome RV is forecasted to be $11.68 million, down from $13.40 million year-over-year [8] Stock Performance - Winnebago shares have decreased by 8.9% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [8] - The company holds a Zacks Rank of 5 (Strong Sell), indicating expectations of underperformance relative to the overall market in the near future [8]

Company Overview - Advanced Energy Industries (AEIS) shares increased by 3.6% to close at $128.97, supported by higher trading volume compared to normal sessions [1] - The stock has gained 5% over the past four weeks, driven by increased demand in the semiconductor and data center computing markets [1] Earnings Expectations - AEIS is expected to report quarterly earnings of $1.28 per share, reflecting a year-over-year increase of 50.6% [2] - Projected revenues for the upcoming report are $419.09 million, which is a 14.8% increase from the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for AEIS has been revised 7.4% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - AEIS operates within the Zacks Semiconductor Equipment - Wafer Fabrication industry, where ASML is another notable player [3] - ASML's consensus EPS estimate has increased by 0.7% to $5.87, representing a year-over-year change of 35.9% [4] - ASML currently holds a Zacks Rank of 2 (Buy), indicating a more favorable outlook compared to AEIS [4]